Biotech and Pharmaceuticals Life Sciences

More

  • LONDON, June 22- Roche is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday. Big wins for three new drugs in recent months have helped to offset what Roche's Severin Schwan acknowledges as a serious...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine. In February, the World Health Organization declared Zika a global public health emergency. India's Bharat Biotech is another company that is in the...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval to start an early stage human trial testing their Zika vaccine. The early-stage study will enroll 40 healthy subjects and evaluate safety, tolerability and immune response generated by the vaccine GLS-5700. "We plan to dose our first...

  • CHICAGO, June 4- Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the American Society of Clinical Oncology in...

  • May 31- Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease. The company, run by former Nestle global research head Andrea Pfeifer, joins other European biotech firms that have opted to list...

  • May 31- StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent. The Newark, California- based biotech said it had cash and cash equivalents of about $5.5 million as of May 31. "In the end, a combination of the tough market environment and long...

  • Modern medicine's latest tool? Gene editing

    CNBC's Meg Tirrell talks with Dr. Jennifer Doudna, UC Berkeley professor and CRISPR technology pioneer about the scientific breakthrough of editing genes as a possible cure for hundreds of diseases.

  • BRIEF-GSK SAYS GENE THERAPY FOR IMMUNE DISORDER MEETS MAIN. *Key efficacy endpoint for analysis was survival. All 18 patients were alive after a median follow-up of 6.9 years at data cut on 8th may 2014.

  • May 24- France's Sanofi SA is preparing to name candidates it will put forward to replace the entire board of U.S. cancer drug company Medivation Inc as early as Wednesday, according to people familiar with the matter. Medivation shares ended trading on Tuesday in New York at $61.91. Among Sanofi's eight nominees are Michael Campbell, the former chief executive...

  • The repercussions of the Bayer-Monsanto deal

    Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.

  • NEW YORK, May 18- Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology. The results were released on Wednesday ahead of the American Society of Clinical Oncology meeting in...

  • May 18- An experimental Pfizer drug that helps the immune system fight cancer showed early promise against a variety of cancers when used with Merck& Co's immunotherapy Keytruda in a small clinical trial, according to data released on Wednesday. The first wave of successful cancer immunotherapies, such as Keytruda, block mechanisms that tumors use to evade the...

  • Ingestible origami robot

    Researchers at MIT have designed an ingestible "robot" that can unfold inside the body, The Verge reports.

  • NEW YORK, May 3- Former drug executive Martin Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional U.S. charges of securities fraud, a federal prosecutor said on Tuesday. Attorney Winston Paes said at a hearing in federal court in Brooklyn, New York. Shkreli, 33, sparked outrage among patients, medical...

  • Sandy & Joan Weill's $185M gift to neuroscience

    Sandy Weill, Citigroup chairman emeritus and former CEO, and his wife Joan discuss their $185 million gift to the University of California, San Francisco for neuroscience research. They believe that this is the decade that neuroscience catches up to other progress in similar sciences. Sandy Weill also weighs in on the financial sector and the prospects for Citigroup.

  • A three-toed sloth from Costa Rica

    Scientists say humans have changed the world so dramatically that the planet's biodiversity is on the decline.

  • April 5- The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson& Johnson's drug Remicade, to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, made by South Korea's Celltrion Inc and Pfizer Inc's Hospira unit, was the second biosimilar approved by the FDA.

  • Crossfit CEO: We're a threat to the industry, not people's wellbeing

    Greg Glassman, Crossfit Founder & CEO, talks about his fitness revolution at the iCONIC Conference in Seattle.

  • How sleeps improves our productivity: Aetna CEO

    Mark Bertolini, Aetna CEO & chairman, discusses how his company is getting employees to improve their sleep, thus improving the company's bottom line. And Bertolini shares his thoughts on Obamacare.

  • LONDON, April 1- The world's first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes. Around 15 children a year are born in Europe with the ultra-rare genetic disorder, which leaves them unable to make a type of white...